mucormycosis

Clinical pharmacology and practical aspects of isavuconazole use

The steadily increasing incidence of invasive fungal infections, influenced to some extent by the COVID-19 pandemic, caused by both yeast and molds makes it necessary to improve the antifungal therapies used. Historically, azoles have held a key …

Combination of invasive aspergillosis and mucormycosis in children: a case report and the results of a multicenter study

Objective. To study risk factors, etiology, clinical signs and treatment outcomes of invasive aspergillosis (IA) and mucormycosis combination (IAM) in children. Materials and Methods. A retrospective review of Saint-Petersburg register (1998–2021) of patients with IA was done and children with IAM were included. EORTC/MSGERG 2019 criteria were used for diagnosing and treatment results evaluation of invasive mycosis. We presented a clinical case of IAM in a child with acute lymphoblastic leukemia relapse.

Mucormycosis of the bones of the facial skull, nasal cavity and par anasal sinuses in patients with COVID19

Currently, the relevance of the issues of diagnosis and treatment of invasive fungal diseases has increased significantly due to the pandemic of a new coronavirus infection COVID-19 and the massive use of corticosteroids for the treatment. The key …

Mucormycosis following COVID19: clinical case and literature review

Mucormycosis is one of the most aggressive invasive mycoses. The mortality rate of patients with mucormycosis, depending on clinical form and background disease, varies from 30% to 100%. This article provides the first description of mucormycosis in …

Mucormycosis: modern diagnostics and treatment, existing problems and new trends in antifungal therapy

Over the last decade, the introduction of new antifungal drugs and diagnostic procedures has improved the prognosis of hematological patients with invasive fungal disease (IFD), primarily invasive aspergillosis. Despite effective antifungal …

Mucormycosis in children with hematological malignancies: results of a single-center study

Objective. To assess the incidence rate, risk factors and treatment outcomes of mucormycosis in children with hematological malignancies in the large tertiary hematology/oncology center. Materials and Methods. A total of 16 children (9 males/7 females) with mucormycosis were enrolled in a single-center, retrospective study over the period of 2012–2018. All patients had an underlying diagnosis of acute leukemia. Mucormycosis was diagnosed at the different timepoints after chemotherapy (CT) or hematopoietic stem cell transplantation (HSCT) in 15 cases and before CT in 1 case.